Словенија - Словеначки - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

adriapharm d.o.o. - aesculus hippocastanum - kroglica - aesculus hippocastanum 12 c / 1 g - -

Словенија - Словеначки - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

adriapharm d.o.o. - aesculus hippocastanum - kroglica - aesculus hippocastanum 200 c / 1 g - -

Словенија - Словеначки - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

adriapharm d.o.o. - aesculus hippocastanum - kroglica - aesculus hippocastanum 30 c / 1 g - -

Словенија - Словеначки - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

adriapharm d.o.o. - aesculus hippocastanum - kroglica - aesculus hippocastanum 6 c / 1 g - -

Словенија - Словеначки - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

adriapharm d.o.o. - aesculus hippocastanum - kroglica - aesculus hippocastanum 6 c / 1 g - -

Словенија - Словеначки - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aesculus hippocastanum - kroglica - aesculus hippocastanum 1000 c / 1 g - -

Словенија - Словеначки - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aesculus hippocastanum - kroglica - aesculus hippocastanum 1 lm / 1 g - -

Европска Унија - Словеначки - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - oftalmologi - eylea je primerna za odrasle, za zdravljenje:neovascular (mokro) starostna degeneracija rumene pege (amd);vida zaradi degeneracija edem sekundarnega do mrežnice vene (veja rvo ali centralne rvo);vida zaradi diabetično degeneracija edem (dme);vida zaradi kratkovidna choroidal neovascularisation (kratkovidna cnv).

Европска Унија - Словеначки - EMA (European Medicines Agency)

acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotična sredstva - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Европска Унија - Словеначки - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologi - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).